(PBE) Dynamic Biotechnology - Overview
Etf: Biotech, Genome, Pharmaceuticals, Healthcare
Dividends
| Dividend Yield | 1.09% |
| Yield on Cost 5y | 0.99% |
| Yield CAGR 5y | 664.39% |
| Payout Consistency | 31.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.9% |
| Relative Tail Risk | 0.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.81 |
| Alpha | 7.75 |
| Character TTM | |
|---|---|
| Beta | 0.716 |
| Beta Downside | 0.557 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.43% |
| CAGR/Max DD | 0.40 |
Description: PBE Dynamic Biotechnology December 29, 2025
The Invesco Dynamic Biotechnology & Genome ETF (NYSE ARCA: PBE) seeks to track an index of U.S. biotechnology and genome-focused companies, allocating at least 90 % of its assets to the constituent stocks. Because the index is non-diversified, the fund’s performance is tightly linked to the fortunes of a relatively concentrated group of firms engaged in R&D, manufacturing, and commercialization of biotech products and services.
Key metrics to watch include the fund’s expense ratio (0.55 % as of 2024), total assets under management (~ US$ 1.2 billion), and the sector’s growth drivers such as the projected 9 % CAGR in global biotech R&D spending and the pipeline-dependent valuation sensitivity to FDA approval cycles. Additionally, the average forward-looking price-to-sales multiple for the underlying holdings sits near 7×, reflecting high growth expectations but also elevated valuation risk.
For deeper quantitative insights, you might explore the ValueRay platform.
What is the price of PBE shares?
Over the past week, the price has changed by +2.08%, over one month by -0.58%, over three months by +10.05% and over the past year by +21.50%.
Is PBE a buy, sell or hold?
What are the forecasts/targets for the PBE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 93.1 | 11.4% |
PBE Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 265.9m USD (265.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 265.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 265.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.55% (E(265.9m)/V(265.9m) * Re(8.55%) + (debt-free company))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)